ALKERMES | ALKS - Interest Expense On Debt


ALKERMES reported $20.89M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
ALKERMES USD 20.89M 8.62M Mar/2026
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Otsuka Holdings JPY 2.21B 866M Dec/2025
Ovoca Bio EUR 7K 6K Jun/2022
Pfizer USD 671M 40M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025